Activation of Ventrolateral Preoptic Neurons During Sleep

Harvard University, Cambridge, Massachusetts, United States
Science (Impact Factor: 31.48). 02/1996; 271(5246):216-9. DOI: 10.1126/science.271.5246.216
Source: PubMed

ABSTRACT The rostral hypothalamus and adjacent basal forebrain participate in the generation of sleep, but the neuronal circuitry involved
in this process remains poorly characterized. Immunocytochemistry was used to identify the FOS protein, an immediate-early
gene product, in a group of ventrolateral preoptic neurons that is specifically activated during sleep. The retrograde tracer
cholera toxin B, in combination with FOS immunocytochemistry, was used to show that sleep-activated ventrolateral preoptic
neurons innervate the tuberomammillary nucleus, a posterior hypothalamic cell group thought to participate in the modulation
of arousal. This monosynaptic pathway in the hypothalamus may play a key role in determining sleep-wake states.

Download full-text


Available from: Priyattam J Shiromani, Nov 05, 2014
  • Source
    • "The involvement of the hypothalamic preoptic area in the control of the wake-sleep cycle has been described in the literature since the early studies of von Economo, 1930. Over the years the ventrolateral preoptic area (VLPO) was established as the brain area responsible for initiating and maintaining NREMS (Lu et al., 2002; Sherin et al., 1996; Szymusiak et al., 1998). According to the current hypothesis, GABAergic/galaninergic neurons of the VLPO inhibit all wake-promoting areas of the ascending arousal system (Saper et al., 2001, 2005; Fuller et al., 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The parabrachial complex is classically seen as a major neural knot that transmits viscero- and somatosensory information towards the limbic and thalamic forebrain. In the present review we summarize recent findings that imply an emerging role of the parabrachial complex as an integral part of the ascending reticular arousal system, which promotes wakefulness and cortical activation. The ascending parabrachial projections that target wake-promoting hypothalamic areas and the basal forebrain are largely glutamatergic. Such fast synaptic transmission could be even more significant in promoting wakefulness and its characteristic pattern of cortical activation than the cholinergic or mono-aminergic ascending pathways that have been emphasized extensively in the past. A similar role of the parabrachial complex could also apply for its more established function in control of breathing. Here the parabrachial respiratory neurons may modulate and adapt breathing via the control of respiratory phase transition and upper airway patency, particularly during respiratory and non-respiratory behavior associated with wakefulness.
    Respiratory Physiology & Neurobiology 06/2013; 188(3). DOI:10.1016/j.resp.2013.06.019 · 1.97 Impact Factor
  • Source
    • "Zebrafish, from whole brain to synapse This has led to the identification of several nuclei involved in behavioral processes (Hoffman et al., 1993; Sherin et al., 1996; Murphy et al., 2004), but despite good correspondence with neural activity, methods using IEGs have their limitations. Firstly, it is possible that IEGs are only induced when neurons are highly/over activated. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent advances in imaging tools are inspiring zebrafish researchers to tackle ever more ambitious questions in the neurosciences. Behaviorally fundamental conserved neural networks can now be potentially studied using zebrafish from a brain-wide scale to molecular resolution. In this perspective, we offer a roadmap by which a zebrafish researcher can navigate the course from collecting neural activities across the brain associated with a behavior, to unraveling molecular identities and testing the functional relevance of active neurons. In doing so, important insights will be gained as to how neural networks generate behaviors and assimilate changes in synaptic connectivity.
    Frontiers in Neural Circuits 04/2013; 7:76. DOI:10.3389/fncir.2013.00076 · 2.95 Impact Factor
  • Source
    • "Recently, another set of sleep-promoting neurons have been identified within the lateral hypothalamus that are GABAergic. GABA and galanin are inhibitory neurotransmitters that are found in the ventrolateral preoptic area (VLPO) and the median preoptic area (MnPO), both of which are instrumental in the onset of sleep [38] [39]. The sleep-active neurons in the VLPO fire fastest during non- REM sleep, with significant decrease in firing during REM sleep, and are silent during wakefulness [40] [41] [42]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Academic Editor: Birgit Frauscher Copyright © 2012 Todd J. Swick. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Parkinson's disease (PD) has traditionally been characterized by its cardinal motor symptoms of bradykinesia, rigidity, resting tremor, and postural instability. However, PD is increasingly being recognized as a multidimensional disease associated with myriad nonmotor symptoms including autonomic dysfunction, mood disorders, cognitive impairment, pain, gastrointestinal disturbance, impaired olfaction, psychosis, and sleep disorders. Sleep disturbances, which include sleep fragmentation, daytime somnolence, sleep-disordered breathing, restless legs syndrome (RLS), nightmares, and rapid eye movement (REM) sleep behavior disorder (RBD), are estimated to occur in 60% to 98% of patients with PD. For years nonmotor symptoms received little attention from clinicians and researchers, but now these symptoms are known to be significant predictors of morbidity in determining quality of life, costs of disease, and rates of institutionalization. A discussion of the clinical aspects, pathophysiology, evaluation techniques, and treatment options for the sleep disorders that are encountered with PD is presented.
    Parkinson's Disease 12/2012; 14. DOI:10.1155/2012/205471 · 2.10 Impact Factor
Show more